X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Alchemab and MDC will evaluate antibodies using innovative technologies, including the use of high content imaging, high resolution microscopy, spatial transcriptomics to assess endpoints using induced pluripotent stem cell derived neuronal & glial cells.
Lead Product(s): Human Monoclonal Antibody
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Recipient: Medicines Discovery Catapult
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 07, 2022
Details:
Under the agreement, Alchemab’s novel drug discovery platform will be used as a diagnostic tool through the identification of disease biomarkers with potential to inform the development of novel antibody-based therapeutics.
Lead Product(s): Antibody-based therapeutics
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 06, 2021
Details:
The funding will be used to advance Alchemab’s novel platform, designed to identify disease-modifying antibody therapeutics.
Lead Product(s): Antibody
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: RA Capital Management
Deal Size: $82.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing April 15, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
